Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 11, 2018. The document serves as a transaction notification reporting acquisitions of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| January 10, 2018 | Ordinary Shares (25p each) | £13.3289 | 180 shares (aggregate) | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine equity compensation transactions for nine senior executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs (180 shares total across 9 individuals).
- Confirm the transaction price of £13.3289 per share against the market price on January 10, 2018.
- Note that all transactions were executed on the London Stock Exchange.
- Identify the specific executives involved: CEO (E. Walmsley), CFO (S. Dingemans), and other senior leadership.
- Understand that this filing does not reflect the company's overall financial performance for the period.